N-[3,5-Bis(trifluoromethyl)benzyl]-1,2-dihydro-N,2-dimethyl-1-oxo-4-phenyl-3-isoquinolinecarboxamide | 159817-61-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[3,5-Bis(trifluoromethyl)benzyl]-1,2-dihydro-N,2-dimethyl-1-oxo-4-phenyl-3-isoquinolinecarboxamide
• 英文别名: 2-Methyl-1-oxo-4-phenyl-1,2-dihydro-isoquinoline-3-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide；N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,2-dimethyl-1-oxo-4-phenylisoquinoline-3-carboxamide
• CAS: 159817-61-5
• 化学式: C₂₇H₂₀F₆N₂O₂
• 分子量: 518.458
• InChiKey: LPQUXJUIJVQRQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  37
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-[3,5-Bis(trifluoromethyl)benzyl]-1,2-dihydro-N,2-dimethyl-1-oxo-4-phenyl-3-isoquinolinecarboxamide 在 diphosphorus pentasulfide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 N-[3,5-Bis(trifluoromethyl)benzyl]-1,2-dihydro-N,2-dimethyl-4-phenyl-1-thioxo-3-isoquinolinecarboxamide
  参考文献：
  名称：

  Condensed heterocyclic compounds, their production and use

  摘要：

  代表性化合物如6-氯-N-(2,6-二乙氧基苯基)-4-(2-甲基苯基-2-氧代-2H-1-苯并吡喃-3-基)乙酰胺，其化学式为：##STR1## 或其盐类。该化合物具有优异的抑制ACAT（酰基辅酶A胆固醇酰基转移酶）活性、降低血液胆固醇水平以及抑制速激肽受体的作用。本发明还涉及该化合物的制备方法及其应用。

  公开号：

  US05482967A1
• 作为产物：
  描述：

  1,2-dihydro-2-methyl-1-oxo-4-phenyl-3-isoquinolinecarboxylic acid 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 N-[3,5-Bis(trifluoromethyl)benzyl]-1,2-dihydro-N,2-dimethyl-1-oxo-4-phenyl-3-isoquinolinecarboxamide
  参考文献：
  名称：

  Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine

  摘要：

  A series of 4-phenylisoquinolone derivatives were synthesized and evaluated for NK1 (substance P) antagonist activity. Highly potent antagonists, 4-phenyl-3-isoquinolone-N-benzylcarboxamides (11), were discovered from the structure-activity relationship studies on the isoquinolone-urea lead la. Optimization of the activity in this series resulted in the development of 5-phenyl-6-pyrido[3,4-b]pyridine-N-benzylcarboxamides (30) which are highly potent orally active NK1 antagonists. Among the compounds synthesized, N-[3,5-bis(trifluoromethyl)benzyl]7,8-dihydro-N, 7-dimethyl-8-oxo-5-(substituted phenyl)6-pyrido[3,4-b]pyridinecarboxamides (30a,f,g) showed excellent antagonist activities with IC50 values (in vitro inhibition of [I-125]- BH-SP binding in human IM-9 cells) of 0.21-0.34 nM and ED(50) values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, iv) of 0.017-0.030 mg/kg. These compounds exhibited significantly potent activity upon oral administration with ED(50) values of 0.068-0.17 mg/kg. Conformational studies on 30g indicated that the two stable conformers of 30g are quite similar to those of CP-99,994.

  DOI：

  10.1021/jm00016a014

文献信息

• US5482967A
  申请人：——

  公开号：US5482967A

  公开（公告）日：1996-01-09
• US5700810A
  申请人：——

  公开号：US5700810A

  公开（公告）日：1997-12-23
• Condensed heterocyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05482967A1

  公开（公告）日：1996-01-09

  Novel compound represented by the formula: ##STR1## such as 6-Chloro-N-(2,6-diethoxyphenyl)-4-(2-methylphenyl-2-oxo-2H-1-benzopyran-3- acetamide: ##STR2## or a salt thereof. The compound has an excellent activity of inhibiting ACAT, lowering the cholesterol in blood and inhibiting tachykinin receptor. The present invention also relates to the production and use of the disclosed compound.

  代表性化合物如6-氯-N-(2,6-二乙氧基苯基)-4-(2-甲基苯基-2-氧代-2H-1-苯并吡喃-3-基)乙酰胺，其化学式为：##STR1## 或其盐类。该化合物具有优异的抑制ACAT（酰基辅酶A胆固醇酰基转移酶）活性、降低血液胆固醇水平以及抑制速激肽受体的作用。本发明还涉及该化合物的制备方法及其应用。
• Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine
  作者：Hideaki Natsugari、Yoshinori Ikeura、Yutaka Kiyota、Yuji Ishichi、Takenori Ishimaru、Osamu Saga、Hideo Shirafuji、Toshimasa Tanaka、Izumi Kamo

  DOI：10.1021/jm00016a014

  日期：1995.8

  A series of 4-phenylisoquinolone derivatives were synthesized and evaluated for NK1 (substance P) antagonist activity. Highly potent antagonists, 4-phenyl-3-isoquinolone-N-benzylcarboxamides (11), were discovered from the structure-activity relationship studies on the isoquinolone-urea lead la. Optimization of the activity in this series resulted in the development of 5-phenyl-6-pyrido[3,4-b]pyridine-N-benzylcarboxamides (30) which are highly potent orally active NK1 antagonists. Among the compounds synthesized, N-[3,5-bis(trifluoromethyl)benzyl]7,8-dihydro-N, 7-dimethyl-8-oxo-5-(substituted phenyl)6-pyrido[3,4-b]pyridinecarboxamides (30a,f,g) showed excellent antagonist activities with IC50 values (in vitro inhibition of [I-125]- BH-SP binding in human IM-9 cells) of 0.21-0.34 nM and ED(50) values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, iv) of 0.017-0.030 mg/kg. These compounds exhibited significantly potent activity upon oral administration with ED(50) values of 0.068-0.17 mg/kg. Conformational studies on 30g indicated that the two stable conformers of 30g are quite similar to those of CP-99,994.